Amicus Therapeutics Company Description

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.

The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease.

It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold.

Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics, Inc.

Country	United States
Founded	2002
Industry	Biological Products, Except Diagnostic Substances
Employees	499
CEO	Bradley Campbell

Contact Details

Address: 47 Hulfish Street Princeton, Delaware 08542 United States
Phone	609 662 2000
Website	amicusrx.com

Stock Details

Ticker Symbol	AM6
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Bradley Campbell	Chief Executive Officer
Simon Nicolas Harford	Chief Financial Officer
Andrew Faughnan	Head of Investor Relations